Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(17)
BIOLOGICAL(3)
PROCEDURE(1)
DRUG(1)
BL22 immunotoxin
3 trials
phase_1
national-cancer-institute-nci, medimmune-llc
LMB-2 immunotoxin
2 trials
not_applicablephase_1
national-institutes-of-health-clinical-center-cc, national-cancer-institute-nci
immunotoxin therapy
2 trials
phase_1
medimmune-llc, national-cancer-institute-nci
polymerase chain reaction
1 trial
national-institutes-of-health-clinical-center-cc
cyclophosphamide
1 trial
not_applicable
national-institutes-of-health-clinical-center-cc
mutation analysis
1 trial
national-institutes-of-health-clinical-center-cc
BL22
1 trial
phase_2
medimmune-llc
SS1(dsFv)-PE38 immunotoxin
1 trial
phase_1
national-cancer-institute-nci

+10 more interventions

18 unique interventions4 categories

Analytics

Trial Phases

Phase 15
Phase 21

Trial Status

Completed5
Terminated1
Other2

Role Distribution

Principal Investigator2
Other Roles6
PI Rate25%

Activity Timeline

Clinical Trials (8)

NCT00002765Phase 1Completed
Immunotoxin in Treating Patients With Leukemia or Lymphoma
LeukemiaLymphoma
Studychair
NCT00006981Phase 1Completed
Immunotoxin Therapy in Treating Patients With Advanced Cancer
Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
Studychair
NCT00021983Phase 1Completed
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
Leukemia
Studychair
NCT00024115Phase 1Withdrawn
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
LeukemiaLymphoma
Studychair
NCT00074048Phase 2Completed
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
Leukemia
Studychair
NCT00126646Phase 1Completed
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
LeukemiaLymphoma
Principalinvestigator
NCT00389506Not ApplicableWithdrawn
Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma
Lymphoma
Studychair
NCT00904514Terminated
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
Cancer
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Lung CancerCancer of PancreasCancer of the Uterine Cervix+2 more
Similarity Score14%

Steven A Rosenberg, M.D.

National Cancer Institute (NCI)

Related
32 trials

Shared therapeutic areas:

Ovary CancerCancer of PancreasCancer of the Uterine Cervix+1 more

Worked with same sponsors:

National Cancer Institute (NCI)National Institutes of Health Clinical Center (CC)
Similarity Score11%

Hagop Youssoufian, MD

Verastem, Inc.

Related
20 trials

Shared therapeutic areas:

LymphomaOvary CancerCancer of Pancreas
Similarity Score8%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

LeukemiaCancerLymphoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lung CancerCancer of Head and NeckOvary Cancer
Similarity Score8%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

Related
13 trials

Shared therapeutic areas:

Ovary CancerCancer of the Uterine CervixCancer of Pancreas
Similarity Score8%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Lung CancerCancerCancer of Head and Neck

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Related
13 trials

Shared therapeutic areas:

Cancer of Head and NeckLymphomaOvary Cancer
Similarity Score8%

Lizhi Niu, PhD

Fuda Cancer Hospital

Related
31 trials

Shared therapeutic areas:

Cancer of PancreasLung Cancer
Similarity Score5%

loic MONDOLONI

Assistance Publique Hopitaux De Marseille

Related
28 trials

Shared therapeutic areas:

CancerLeukemia
Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (8)

Showing 8 of 8 trials

NCT00002765Phase 1StudyChair

Immunotoxin in Treating Patients With Leukemia or Lymphoma

LeukemiaLymphoma
Completed
NCT00006981Phase 1StudyChair

Immunotoxin Therapy in Treating Patients With Advanced Cancer

Cervical CancerFallopian Tube CancerHead and Neck Cancer+5 more
Completed
NCT00021983Phase 1StudyChair

Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia

Leukemia
Completed
NCT00024115Phase 1StudyChair

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

LeukemiaLymphoma
Withdrawn
NCT00074048Phase 2StudyChair

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Leukemia
Completed
NCT00126646Phase 1PrincipalInvestigator

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

LeukemiaLymphoma
Completed
NCT00389506Not ApplicableStudyChair

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Lymphoma
Withdrawn
NCT00904514PrincipalInvestigator

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Cancer
Terminated

All 8 trials loaded